A detailed history of Nisa Investment Advisors, LLC transactions in Geron Corp stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 6,116 shares of GERN stock, worth $26,359. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,116
Previous 5,729 6.76%
Holding current value
$26,359
Previous $18,000 38.89%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$3.1 - $5.09 $1,199 - $1,969
387 Added 6.76%
6,116 $25,000
Q1 2024

May 01, 2024

BUY
$1.75 - $3.44 $873 - $1,716
499 Added 9.54%
5,729 $18,000
Q4 2023

Jan 25, 2024

SELL
$1.74 - $2.31 $17 - $23
-10 Reduced 0.19%
5,230 $11,000
Q3 2023

Nov 02, 2023

SELL
$2.11 - $3.28 $19,475 - $30,274
-9,230 Reduced 63.79%
5,240 $11,000
Q2 2023

Aug 11, 2023

BUY
$1.97 - $3.69 $6,008 - $11,254
3,050 Added 26.71%
14,470 $46,000
Q1 2023

May 02, 2023

BUY
$2.14 - $3.4 $13,225 - $21,012
6,180 Added 117.94%
11,420 $25,000
Q4 2022

Feb 02, 2023

BUY
$2.03 - $2.42 $180 - $215
89 Added 1.73%
5,240 $13,000
Q3 2022

Nov 07, 2022

BUY
$1.67 - $2.94 $519 - $914
311 Added 6.43%
5,151 $11,000
Q4 2021

Feb 03, 2022

SELL
$1.22 - $1.72 $206,199 - $290,707
-169,016 Reduced 97.22%
4,840 $5,000
Q3 2021

Oct 18, 2021

BUY
$1.2 - $1.5 $146,959 - $183,699
122,466 Added 238.31%
173,856 $238,000
Q2 2021

Aug 06, 2021

BUY
$1.25 - $1.83 $58,187 - $85,186
46,550 Added 961.78%
51,390 $72,000
Q4 2020

Jan 25, 2021

BUY
$1.55 - $2.05 $2,557 - $3,382
1,650 Added 51.72%
4,840 $8,000
Q3 2019

Oct 17, 2019

BUY
$1.15 - $1.59 $2,438 - $3,370
2,120 Added 198.13%
3,190 $4,000
Q3 2018

Oct 16, 2018

BUY
$1.76 - $6.38 $1,883 - $6,826
1,070 New
1,070 $2,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.63B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.